id: NEW:pharmacological_treatment_for_antisocial_personality_disorder_to_NEW:global_state_functioning
name: Pharmacological Treatment for Antisocial Personality Disorder â†’ Global State/Functioning
from_node:
  node_id: NEW:pharmacological_treatment_for_antisocial_personality_disorder
  node_name: Pharmacological Treatment for Antisocial Personality Disorder
to_node:
  node_id: NEW:global_state_functioning
  node_name: Global State/Functioning
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Antidepressant (nortriptyline) or dopamine agonist (bromocriptine) administered to individuals
  with AsPD and comorbid alcohol dependency'
- 'Step 2: Medications may modulate neurotransmitter systems involved in mood and impulse regulation'
- 'Step 3: No significant difference observed in global state/functioning scores between treatment and
  placebo groups'
evidence:
  quality_rating: C
  n_studies: 2
  primary_citation: Najat R Khalifa et al. 2020. "Pharmacological interventions for antisocial personality
    disorder.." https://doi.org/10.1002/14651858.CD007667.pub3
  supporting_citations:
  - 'Nortriptyline study: 20 participants with AsPD and alcohol dependency'
  - 'Bromocriptine study: 18 participants'
  - Additional citations require full-text access
  doi: 10.1002/14651858.CD007667.pub3
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Very low certainty evidence from two small studies found no significant difference between
  nortriptyline (mean GSI=0.3 vs placebo=0.7) or bromocriptine (mean GSI=0.4 vs placebo=0.7) and placebo
  on global state/functioning measured by SCL-90 Global Severity Index at 6 months in individuals with
  AsPD and alcohol dependency.
quantitative_effects:
  sample_size: 38
spatial_variation:
  varies_by_geography: true
  variation_notes: Studies predominantly conducted in North America; applicability to other healthcare
    systems uncertain
moderators:
- name: alcohol_dependency_comorbidity
  direction: weakens
  strength: moderate
  description: Participants had comorbid alcohol dependency which may affect treatment response and complicate
    interpretation of AsPD-specific effects
- name: adverse_effects
  direction: weakens
  strength: strong
  description: Bromocriptine caused severe side effects in 12 patients with 5 dropping out within first
    two days due to nausea and flu-like symptoms
structural_competency:
  equity_implications: The intersection of AsPD with alcohol use disorder highlights the need for integrated
    treatment approaches addressing both conditions. Structural barriers to treatment include lack of
    specialized services, stigma associated with personality disorders, and healthcare system fragmentation.
    The high attrition due to adverse effects in the bromocriptine study suggests need for better tolerated
    treatments, particularly for vulnerable populations who may have limited healthcare access and support
    systems.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.351469'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
